Structural insights into inhibition mechanism of the helicase-primase complex from human herpesvirus 1

This study reports cryo-EM structures of the human herpesvirus 1 helicase-primase complex bound to inhibitors amenamevir and pritelivir, revealing how these drugs lock the helicase in an inactive conformation to provide a structural basis for developing antivirals against other herpesvirus subfamilies.

The Gist

The Big Picture: Stopping a Viral Construction Crew

Imagine a virus (specifically Herpes Simplex Virus 1) as a tiny, chaotic construction crew trying to build a massive wall of DNA to replicate itself. To do this, they need two main workers:

1. The Demolition Crew (Helicase): Their job is to unzip the double-stranded DNA so the builders can see the blueprint.
2. The Blueprint Writers (Primase): Their job is to write down the starting instructions (primers) so the builders can start laying bricks.

In the herpes virus, these two workers are glued together in a single machine called the Helicase-Primase Complex (HPC). If you stop this machine, the virus can't copy itself, and the infection stops.

The Problem: We Didn't Know How the Locks Worked

Scientists have known about two powerful drugs that stop this machine: Amenamevir and Pritelivir. They are like master keys that jam the gears. However, for years, we didn't know exactly how they worked. It was like seeing a car stop working because someone put a rock in the engine, but not knowing where the rock was or how it jammed the pistons.

Without knowing the exact mechanism, it's hard to design new drugs for other types of herpes viruses (like the ones that cause chickenpox or shingles) that these current drugs don't work on.

The Discovery: Taking a 3D Snapshot

The researchers in this paper used a high-tech camera called Cryo-EM (think of it as a super-microscope that takes 3D photos of frozen molecules) to snap a picture of the viral machine while it was being stopped by these drugs.

Here is what they found, using some simple analogies:

1. The Machine Has Two Parts

The viral machine isn't a solid block; it's like a flexible robot arm with two main sections:

• The Head (Helicase Module): Does the heavy lifting of unzipping DNA.
• The Hand (Primase Module): Writes the instructions.
  The researchers found that these two parts can wiggle and move relative to each other.

2. The "Open" Trap

Normally, for the machine to work, the "Head" needs to snap shut like a clam shell to grab energy (ATP) and pull the DNA.

• The Drug's Trick: The researchers discovered that both drugs sneak into a hidden pocket near the energy slot (but not inside it).
• The Result: Once the drug is in, it acts like a wedge in a door. It forces the "Head" of the machine to stay wide open. Because it's stuck open, it can't grab the energy it needs. The machine is paralyzed, frozen in an "open" position, and the virus dies.

3. Why One Drug Works Better Than the Other

The paper also explains why Amenamevir works on all types of alpha-herpes viruses, while Pritelivir is a bit more picky.

• The Analogy: Imagine the drug binding pocket is a glove.
  • Amenamevir is like a glove with a stretchy cuff. It fits snugly on almost any hand (all alpha viruses).
  • Pritelivir is like a glove with a very specific, stiff thumb. It fits perfectly on one hand, but if the hand is slightly different (like in the chickenpox virus), the stiff thumb bumps into the skin, and the glove won't fit.
• The Science: The researchers used supercomputer simulations to show that a tiny chemical difference in Pritelivir creates a "bump" that prevents it from fitting into the pockets of other virus types.

Why This Matters

This study is a huge win for drug design.

1. We have the blueprint: Now that we have the 3D map of the machine and the drugs, scientists can design new drugs that fit perfectly into the "wedge" spot.
2. Targeting the untreatable: By understanding exactly which parts of the machine are different between virus types, scientists can now try to build new "gloves" (drugs) that fit the beta and gamma herpes viruses (which cause serious diseases in people with weak immune systems) that we currently can't treat effectively.

Summary

In short, the researchers took a high-resolution photo of a viral machine, figured out that two existing drugs work by jamming the machine open so it can't move, and used computer models to explain why those drugs work on some viruses but not others. This gives us the instructions needed to build better, broader-spectrum antiviral medicines for the future.

Technical Summary

1. Problem Statement

Human herpesviruses (HHVs) are ubiquitous pathogens causing severe diseases, particularly in immunocompromised individuals, and are linked to neurodegenerative disorders. While antiviral therapies exist for the $\alpha$-subfamily (HHV1, HHV2, HHV3), effective treatments for the $\beta$- and $\gamma$-subfamilies are scarce. The helicase-primase complex (HPC), essential for viral DNA replication, is a validated drug target. However, the lack of high-resolution structural data regarding the HPC's architecture and its interaction with inhibitors has hindered the rational design of next-generation antivirals. Specifically, the mechanisms by which clinical inhibitors amenamevir (AMNV) and pritelivir (PTV) function, and why they exhibit limited efficacy against non-$\alpha$ subfamilies, remained elusive.

2. Methodology

The authors employed an integrated structural biology and computational approach:

• Sample Preparation: Reconstituted the HHV1 HPC (subunits UL5, UL52, UL8) in insect cells and purified the complex. Complexes were formed with single-stranded DNA (ssDNA), a non-hydrolyzable ATP analog (AMP-PNP), and either AMNV or PTV.
• Cryo-Electron Microscopy (Cryo-EM): Collected data using a Titan Krios G4 microscope. Due to the inherent flexibility of the complex, they utilized 3DFlex refinement and focused local refinement to resolve the Helicase Module (HM) and Primase Module (PM) independently, achieving resolutions of 2.88–3.32 Å.
• Biochemical Assays: Conducted ATPase inhibition assays to determine kinetic parameters ($K_m$, $K_i^{app}$) and inhibition mechanisms under varying ATP concentrations.
• Molecular Dynamics (MD) Simulations: Performed 24 $\mu$s of MD simulations (8 replicas $\times$ 3 $\mu$s per system) on UL5-UL52 subcomplexes (with and without inhibitors) to analyze conformational dynamics and water-mediated interactions.
• Fragment Molecular Orbital (FMO) Calculations: Used quantum chemical calculations (MP2/6-31G*) on clustered MD snapshots to quantitatively decompose interaction energies (electrostatic, exchange-repulsion, charge transfer, dispersion) between inhibitors and protein residues.

3. Key Contributions

• First High-Resolution Structures: Provided the first cryo-EM structures of the HHV1 HPC bound to ssDNA and clinical inhibitors (AMNV and PTV).
• Mechanism of Inhibition: Elucidated that these inhibitors act as allosteric inhibitors that function competitively with ATP by locking the helicase in an open, inactive conformation.
• Structural Basis for Selectivity: Identified specific molecular determinants explaining the $\alpha$-subfamily specificity and the distinct antiviral spectra of AMNV vs. PTV.
• Integrated Methodology: Demonstrated the power of combining Cryo-EM, MD, and FMO to resolve dynamic mechanisms and water-mediated interactions that static structures alone cannot capture.

4. Key Results

A. Overall Architecture and Flexibility

• The HPC is organized into two flexible modules:
  • Helicase Module (HM): Contains the entire UL5 helicase and two domains of UL52 (Scaffold Domain and Zinc-Binding Domain).
  • Primase Module (PM): Contains the Primase Domain of UL52 and the accessory subunit UL8.
• The relative orientation of the HM and PM is highly flexible, suggesting a dynamic reorientation is required for the coupling of DNA unwinding and primer synthesis.

B. Inhibition Mechanism

• Binding Site: Both AMNV and PTV bind to a shared allosteric pocket located at the interface between the UL52 Scaffold Domain and the UL5 linker region (motif IIIa), distinct from the ATP-binding cleft.
• Conformational Locking: The inhibitors stabilize the helicase in an "open" conformation. In this state, the distance between the ATP-binding motifs (Motif I in domain 1A and Motif VI in domain 2A) is too large to coordinate ATP binding.
• Biochemical Evidence: ATPase assays showed that increasing ATP concentrations increased the apparent inhibition constant ($K_i^{app}$), confirming a competitive relationship. The large $\alpha$ factors derived from mixed inhibition models indicate the inhibitors bind the free enzyme much more strongly than the enzyme-ATP complex.
• MD Simulation: Simulations revealed that without inhibitors, the catalytic domains fluctuate between open and closed states. In the presence of inhibitors, the complex is locked in the open state, preventing the "inchworm" motion required for DNA unwinding.

C. Specificity and Resistance

• Common Interactions: Both drugs interact with conserved residues (e.g., UL5 K356, UL52 N902) via hydrogen bonds and hydrophobic contacts.
• AMNV Specificity: AMNV possesses a unique dimethylphenyl group that engages in strong $\pi$-$\pi$ and CH/$\pi$ interactions with conserved residues UL5 Y882 and UL52 F360. These residues are conserved across all $\alpha$-herpesviruses, explaining AMNV's broad efficacy against HHV1, HHV2, and HHV3.
• PTV Specificity: PTV lacks the dimethylphenyl group but features a sulfonamide NH$_2$ group. FMO analysis revealed a critical hydrogen bond between this NH$_2$ group and the carbonyl oxygen of UL52 A899.
  • In HHV3 (VZV), the corresponding residue is Valine (V), which introduces steric hindrance, disrupting this bond and explaining PTV's limited activity against HHV3.
  • Resistance mutations (e.g., A899T in UL52) disrupt this specific interaction, conferring resistance to PTV but not AMNV.

5. Significance

• Drug Design Framework: This study provides a structural blueprint for designing novel HPIs with tailored specificity. By targeting the specific residues that differ between $\alpha$, $\beta$, and $\gamma$ subfamilies (particularly in UL52), new drugs can be developed to treat currently untreatable herpesvirus infections.
• Mechanistic Insight: It resolves the long-standing question of how HPIs inhibit the HPC, revealing a mechanism where allosteric binding prevents the conformational changes necessary for ATP hydrolysis.
• Methodological Advance: The successful integration of Cryo-EM with MD and FMO calculations sets a new standard for studying flexible macromolecular complexes and elucidating drug binding thermodynamics, particularly for water-mediated interactions and quantum mechanical effects.